Background: Classification of refractory celiac disease (RCD) is based on the presence or absence of monoclonal expansions of intraepithelial lymphocytes (IELs) with an aberrant immunophenotype.
Study: IEL phenotype by immunohistochemistry and T-cell receptor (TCR) gene rearrangement by polymerase chain reaction were assessed in 73 RCD patients (type I = 67, type II = 6). Detection of a monoclonal TCR gene rearrangement and presence of <50% CD3 + CD8 + IELs were considered abnormal. Time to worsening of clinical symptoms and predictors of worsening were calculated by Kaplan-Meier and Cox proportional hazard analyses.
Results: Fewer than 50% CD3
+ CD8 + IELs were detected in 30 patients and monoclonal TCR rearrangements in 6. Three patients died and 40 suffered clinical worsening despite treatment. Estimated 5-year survival rates decreased from 100% in patients with >50% CD3 + CD8 + IELs and polyclonal TCR to 88% and 50% in patients with <50% CD3 + CD8 + IELs and monoclonal TCR, respectively. Clinical worsening was more frequent (100%) among patients harboring a monoclonal TCR gene rearrangement with <50% CD3 + CD8 + IELs. These patients also showed shorter median time to clinical worsening (11 mo) when compared to patients with <50% CD3 + CD8 + IELs alone (21 mo), polyclonal TCR (38 mo), or >50% CD3 + CD8 + IELs alone (66 mo). After adjusting for age and gender, only the presence of <50% CD3 + CD8
+ IELs was associated with increased risk for clinical worsening despite negative celiac serologies (hazard ratio = 4.879; 95% confidence interval, 1.785-13.336; P = 0.002).
Conclusions: Presence of <50% CD3
+ CD8 + IELs is a risk factor for clinical worsening in RCD and combined with a monoclonal TCR gene rearrangement result is associated with increased mortality. IEL phenotype and TCR gene rearrangement analyses provide differential information regarding morbidity and mortality in RCD.
Key Words: intraepithelial lymphocytes, refractory celiac disease, T-cell receptor gene rearrangement, phenotype, mortality, morbidity (J Clin Gastroenterol 2013;00:000-000) R efractory celiac disease (RCD) is an infrequent complication of celiac disease (CD) that is defined as the persistence of symptoms and villous atrophy (VA), despite a strict gluten-free diet (GFD) for >12 months. 1 The prognosis varies substantially depending on the subtype. 2, 3 RCD subtype is determined by the presence (type II) or absence (type I) of aberrant small intestinal intraepithelial lymphocytes (IELs). 4, 5 In normal individuals and in patients with uncomplicated CD, IELs express surface CD3 and CD8 antigens (detectable by immunohistochemistry or flow cytometry) and display polyclonal T-cell receptor (TCR) b or g gene rearrangement products on polymerase chain reaction (PCR) analysis. 6 Patients with RCD type II, however, have a proportion of aberrant IELs that, while retaining intracytoplasmic CD3 expression, lose surface CD3 and CD8 expression. 4, 6 This CD3 À CD8 À phenotype (CD3 + CD8 À by immunohistochemistry) is frequently, but not always, associated with the presence of a monoclonal IEL population by TCR gene rearrangement analysis. Of note, cases of RCD type II with a CD8 + IEL phenotype have been reported. [6] [7] [8] Analysis of IEL phenotype by immunohistochemistry and/or TCR gene rearrangement by PCR analysis has, therefore, become part of the diagnostic workup of RCD.
Although RCD type I has survival rates between 58% and 96%, RCD type II is associated with poor survival and transformation to overt enteropathy-associated T-cell lymphoma (EATL) in 50% to 60% of cases within 5 years. 9 Furthermore, patients who develop EATL have extremely poor prognosis with an overall 2-year survival rate of 15% to 20%. 9 Recognition and treatment of RCD is thus of utmost importance. However, current treatment regimens for RCD type II, although promising, 4, [10] [11] [12] are ineffective, 1 and between 45% and 60% of patients die within 5 years despite aggressive therapy. 2, [13] [14] [15] [16] Refractoriness to therapy has been associated with the detection of monoclonal IEL populations or clonal TCR gene rearrangement products in small bowel biopsy samples of CD patients or with the development of EATL. 6, 17 Few studies, however, have examined the utility of determining different IEL parameters in the evaluation of clinical outcomes in RCD patients. Moreover, there are conflicting data on the role of T-cell monoclonality as a predictor of poor prognosis in RCD. Some studies have shown an association between detection of monoclonal TCR gene rearrangement and mortality, whereas others have questioned the prognostic impact of detecting clonal IEL populations. 2, 13 Methodological differences among studies, such as variability in follow-up duration, number of confounding variables examined, and differences among studies in the criteria used for classification into RCD type I and type II, 2, [13] [14] [15] [16] 18 are potential explanations for the inconsistent results. Furthermore, data on predictors of clinical outcomes other than death have not been reported for RCD patients.
As the classification of RCD is based on IEL parameters, we hypothesized that evaluation of different IEL parameters may provide distinct prognostic information regarding mortality and morbidity in RCD than the previously used classifiers. The aim of the present study was to assess the prognostic import of IEL phenotype and results of TCR gene rearrangement analysis on the mortality and morbidity of RCD patients. More specifically, we investigated the impact of detecting increased numbers of CD3 + CD8 À IELs in small bowel biopsies by immunohistochemistry or detecting monoclonal TCR rearrangements by PCR analysis on measures of morbidity and mortality. Our study focused mostly on RCD type I patients and aimed to determine how immunohistochemistry and PCR findings could help assess the clinical prognosis of such patients, who represent a larger and more commonly encountered group than RCD type II and for whom not much is known regarding prognostic parameters.
MATERIALS AND METHODS

Subjects
Records from 700 biopsy-proven (Marsh 3) CD patients seen at our institution between 1981 and 2005 were retrospectively reviewed for results of TCR gene rearrangement analysis and immunohistochemical staining for CD3 and CD8. Patients with persistent VA in the follow-up biopsy and with persistent or recurrent symptoms despite being on a GFD for at least 12 months (or 6 mo if they required steroids, immunomodulators, or parenteral nutrition for control of severe symptoms) were considered to have refractory disease. After excluding patients with other possible causes of persistent VA and symptoms on the basis of endoscopy, imaging, serology, or histopathologic findings, only RCD patients on a strict GFD, as assessed by an expert dietician at the time of diagnosis (n = 77), were considered for the study. Of these patients, those who presented with an EATL (n = 4) were excluded from the final analysis. Data regarding age and mode of presentation at CD diagnosis as well as date and serology at RCD diagnosis were recorded. Information on associated autoimmune diseases, stool cultures, and treatment of RCD was also reviewed. The study was approved by our Institutional Review Board and all patients provided signed informed consent.
Clinical Outcome
Clinical outcome was assessed at every follow-up visit by the diagnosing physician after initiation of treatment for RCD. "Clinical improvement" was defined as disappearance, or marked amelioration, of symptoms that no longer interfered with activities of daily living (work and/or self-care at home) and that required minimal medical care or medication for disease management. "Clinical worsening" was defined as the occurrence, relapse, or worsening of symptoms lasting >1 week despite medical treatment after the diagnosis of RCD that led to a stage of disability in which individuals were incapable of self-care and required medical assistance in an intermediate care facility or hospital, or if they needed palliative medication (eg, total parenteral nutrition).
Histopathology
Small bowel biopsies of patients taken at the time of RCD diagnosis were blindly reviewed by an expert pathologist. The degree of VA was determined on well-oriented biopsies using the Marsh-Oberhuber modified classification as partial, subtotal, or total VA, corresponding to Marsh stages 3a, 3b, and 3c, respectively. 19 For analytical purposes, VA was later dichotomized as mild (grade 3a) and severe (grades 3b and 3c). Small bowel biopsies were also evaluated for the presence of collagenous sprue and colonic biopsies for microscopic colitis.
Immunohistochemistry
Immunohistochemical staining was performed on 4-mm sections of 10% formalin-fixed, paraffin-embedded small bowel biopsies using an indirect immunoperoxidase technique with antibodies directed against human T-cell antigens CD3 and CD8 (Dako, Carpinteria, CA). The percentage of CD3 + IELs that expressed CD8 was calculated, and cases with <50% of IELs expressing CD8 (<50% CD3 + CD8 + ) were considered "abnormal," whereas cases with Z50% CD8 + IELs (>50% CD3 + CD8 + ) were considered "normal"; these values were used as they are the most common cutoff values used by prior investigators. 13, 18, 20 TCR Gene Rearrangement Analysis PCR analysis for TCR gene rearrangement was performed using DNA extracted from the biopsies that were used for immunohistochemical staining. The TCR-g gene V-J region was amplified by multiplexed PCR followed by heteroduplex analysis and polyacrylamide gel electrophoresis. 21 The presence of 1 prominent peak was considered monoclonal, a smear pattern polyclonal, and 2 (or more) distinct peaks oligoclonal.
Disease Classification
Refractoriness to GFD was considered "primary" if there was no initial clinical response to a GFD and as "secondary" if symptoms recurred after initial response. 22 The mode of presentation was classified according to the Oslo definitions for CD as "classical" if the predominant symptom was diarrhea, with or without weight loss, and as "nonclassical" if the main symptom did not include diarrhea or weight loss (abdominal pain, anemia, fatigue, etc.). 23 For the purpose of analyzing clinical outcomes based on the type of RCD, patients with a monoclonal TCR gene rearrangement were considered as having RCD type II and those with polyclonal or oligoclonal results as having RCD type I, as these are the most common features in prior publications.
Statistical Analyses
Descriptive statistics are presented by type of RCD. The demographic and clinical characteristics of RCD type I and type II patients were compared using the Pearson w 2 test, the Fisher's exact test or the t test as appropriate. Kaplan-Meier survival curves were built for each predictor variable to evaluate the effect of IEL parameters on time to death (overall survival) or on time to clinical worsening (progression-free survival). The progression-free period was calculated from the date of RCD diagnosis until onset of the severe symptoms or death, whichever occurred first. Follow-up was performed retrospectively (ie, based on reports, without directly contacting the patient) and that cases were censored either at the end of the study on December 31, 2005 or on the last available follow-up visit if the event (ie, clinical worsening) did not occur. Survival curves were compared using the 2-tailed log-rank test. Univariate Cox regression analyses were performed to estimate hazard ratios (HR), and multivariate Cox proportional hazard regression was used to identify riskadjusted predictors of clinical worsening in RCD. In addition, the Cox proportional hazard model was evaluated for interaction between predictor variables. Nonparametric tests were used when appropriate. Results are expressed as mean ± SE of the mean, as median (m) and range, and as HR with 95% confidence interval (CI). All P values were 2-tailed and significance level was set at <0.05. All analyses were performed using SPSS 18.0 statistical software (SPSS Inc., Chicago, IL).
RESULTS
Demographics and Clinical Characteristics
Characteristics of the study patients, overall and by RCD subtype, are shown in Table 1 . Out of 700 biopsyproven CD patients, at the start of follow-up, a total of 73 patients with RCD (type I = 67 and type II = 6) fulfilled our inclusion criteria of persistent Marsh 3 grade VA and persistent symptoms not attributable to another disease despite compliance with a GFD. The mean age of the patients was 55.8 years (range, 16 to 87 y) with a predominance of the female gender (78%), as expected for CD. The overall median follow-up interval after RCD diagnosis was 21 months, the longest being 102 months and the shortest being 1 month. Most RCD patients presented with classical symptoms (86%) and were almost equally distributed between primary and secondary nonresponders to a GFD. Six patients had a monoclonal product on PCR analysis for TCR gene rearrangement and thus were classified as RCD type II. Fifty-nine patients with RCD type I had polyclonal products on PCR analysis for TCR gene rearrangement, whereas 8 displayed an oligoclonal pattern. Thirty (41%) patients had <50% CD3 + CD8 + IELs by immunohistochemical staining, of which 24 (80%) were type I and 6 (20%) were type II. Histopathologic examination demonstrated that 59% of patients (type I = 63% and type II = 17%) had mild VA at the time of diagnosis. The majority of patients (34%) received 2 immunosuppressive medications (mainly budesonide and azathioprine), 19% were on GFD alone, and 8% were on single-agent immunosuppressive therapy (systemic steroids). A total of 18% required supportive therapy in addition to the immunosuppressive medication, such as antibiotics or pancreatic enzymes, and only 1 patient (1%) was treated with aminosalicylates. All patients had serologic information at the time of RCD diagnosis and 22% had a positive serology (antiendomysial and/or antitissue transglutaminase antibodies).
Mortality in RCD
Death occurred in 3 (4%) of 73 patients, all within the first year (median, 8 mo) of diagnosis. The direct causes of death were sepsis (n = 2) and encephalitis (n = 1). + IELs. All patients with the latter 2 features were alive at the end of the study. The 5-year cumulative survival rate was lower in patients with <50% CD3 + CD8 + IELs (87.5%) than in patients with >50% CD3 + CD8 + IELs (100%, P = 0.028) and in patients with monoclonal TCR gene rearrangement (50%) when compared with patients with polyclonal TCR gene rearrangement products (100%, P < 0.0001; data not shown).
Morbidity in RCD
To assess the effect of the percentage of CD3 + CD8
À IELs and TCR gene monoclonality on measures of morbidity, we examined the probability of clinical worsening of symptoms despite treatment by determining the time that lapsed between the diagnosis of RCD and the onset of severe symptoms. Distribution of patients and development of clinical worsening according to the different IEL parameters are shown in Figure 1 . Overall, clinical worsening was observed in 59% of patients (number of events = 43), including the 3 who died. The worsening of symptoms comprised increasing number of diarrheal episodes, abdominal pain, paresthesias, leg edema due to hypoalbuminemia, increasing weight loss, and need for parenteral nutrition. After 8.5 years of follow-up, all the patients with monoclonal TCR gene rearrangements (n = 6) showed clinical worsening, whereas in the polyclonal (n = 59) and oligoclonal group (n = 8) clinical worsening was noted in only half (56% and 50%, respectively) of the patients. Similarly, the incidence of clinical worsening in patients with <50% or >50% CD3 + CD8 + IELs by immunohistochemistry was 70% and 51%, respectively.
Kaplan-Meier progression-free survival curves showed shorter time until onset of severe symptoms when monoclonal TCR gene rearrangements or <50% CD3 + CD8 + IELs were detected by PCR or immunohistochemistry (Fig. 2) . Patients with monoclonal TCR gene rearrangements had a median overall progression-free period of 11 months (95% CI, 0.6-21.4 mo), compared with patients Arguelles
who had polyclonal rearrangement patterns, for whom the period was 38 months (95% CI, 22.1-53.9 mo) (log-rank chi-square = 11.665, P = 0.001). Similar findings were observed for immunohistochemistry-determined phenotype. Those with <50% CD3 + CD8 + IELs presented with severe symptoms earlier (21 mo; 95% CI, 15.2-26.8 mo) than those with >50% CD3 + CD8 + IELs (66 mo; 95% CI, 28.5-103.5 mo; log-rank chi-square = 10.951; P = 0.001). Patients with an oligoclonal TCR gene rearrangement pattern did not have worse clinical outcomes than patients with a polyclonal TCR gene rearrangement pattern and showed a longer progression-free period when compared with patients with a polyclonal or a monoclonal TCR gene rearrangement pattern (73, 38, and 11 mo, respectively; P = 0.002 by log-rank test; Fig. 3 ).
Impact of Comorbid Diseases on Clinical Worsening of RCD Patients According to Subtype
CD is associated with other autoimmune or inflammatory diseases, 15 and RCD patients are at a higher risk of developing these diseases compared with patients with uncomplicated CD. To investigate the impact of these diseases on clinical progression, we studied the presence of autoimmune diseases (diabetes mellitus type I, hypothyroidism, psoriasis, peripheral neuropathy, autoimmune hepatitis), other CD-associated conditions (microscopic colitis, ulcerative jejunitis, osteoporosis, and osteopenia), and CD-unrelated conditions (infection, asthma, cardiomyopathy) in RCD patients. Table 2 shows the distribution of comorbid diseases among type I and type II patients. Out of 73 patients, coexisting diseases were found + CD8 + IELs in the small bowel biopsy (B). Note that all patients with monoclonal TCR-g gene rearrangements had concomitant aberrant (< 50% CD3 + CD8 + ) IELs and that 20% (n = 6) of patients with an aberrant phenotype also had a monoclonal TCR gene rearrangement. P-value by log-rank test. IELs indicates intraepithelial lymphocytes by immunohistochemisrty; m, median; RCD, refractory celiac disease; TCR, T-cell receptor gene rearrangement pattern by polymerase chain reaction analysis. in most (80%). The most frequent entity was osteopenia or osteoporosis (n = 33), followed by microscopic colitis (n = 15), peripheral neuropathy (n = 12), and diabetes mellitus type I (n = 7). We did not find any difference in the frequency of other diseases or disorders between RCD type I and type II (Table 2) , except for microscopic colitis, which was more frequent in RCD type I (n = 15) than in RCD type II (n = 0) patients, although not reaching statistical significance (Fisher = 0.335), and infections, which were more frequent in type II (33%) than in type I (2%) patients (Fisher = 0.016). Failure to detect any differences between the disease subtypes might reflect the small sample size of RCD type II patients in our series. Notably, although autoimmune disease comorbidity was not associated with clinical worsening by Cox regression analysis, CD-unrelated diseases (HR = 1.916, P = 0.040) and other CD-associated diseases (HR = 0.397, P = 0.010) showed an association with clinical worsening (Table 3) . Multivariate Cox regression analysis of each coexisting disease group showed that microscopic colitis (HR = 0.125, P < 0.0001) and osteopenia (HR = 0.193, P = 0.001) were associated with a lower risk for clinical worsening, whereas infection (HR = 8.293, P = 0.008) was associated with a higher risk.
IEL Clonality and Phenotype as Predictors of Clinical Worsening in RCD
All patients with a monoclonal TCR gene rearrangement concomitantly exhibited <50% CD3 + CD8 + IELs. To examine this interaction and to adjust for possible confounders, such as serology, we investigated the effect of <50% CD3 + CD8 + IELs and monoclonal TCR gene rearrangement status on clinical worsening in the context of other prognostic factors using Cox proportional hazard models. We first performed univariate analysis, and the potentially significant variables were then examined by multivariate analysis.
In univariate analysis (Table 3) , potential prognostic parameters for clinical worsening were primary RCD, positive serology at the time of RCD diagnosis, <50% 
CD3
+ CD8 + IELs, and having a monoclonal TCR gene rearrangement. Gender, age, degree of VA, duration of CD, presence of non-EATL lymphoma, clinical presentation at diagnosis, type of treatment, and presence of autoimmune diseases did not lead to worsening of symptoms or to worsening of the clinical course of RCD patients.
After adjusting for age, gender, and serology, multivariate analysis of IEL-related predictors demonstrated that having <50% CD3 + CD8 + T cells, but not the presence of a monoclonal TCR gene rearrangement, was associated with increased risk for clinical worsening among RCD patients (HR = 2.853, P = 0.009 and HR = 1.939, P = 0.215, respectively). Borderline significant association of positive serology with clinical worsening (P = 0.049) and significant interaction between <50% CD3 + CD8 + IELs and positive serology were also observed (P = 0.003). Analysis of the interaction between cases with monoclonal TCR gene rearrangement and <50% CD3 + CD8 + IELs could not be evaluated because of the small sample size. Stratifying by serologic status revealed that patients with <50% CD3 + CD8 + IELs and negative serology were at increased risk for premature clinical worsening (HR = 4.879, P = 0.002) compared with those patients with <50% CD3 + CD8 + IELs and positive serology who did not show an increased risk (HR = 0.349, P = 0.325; Table 4 ). These findings highlight the value of detecting <50% CD3 + CD8 + IELs, alone or in combination with serology, in predicting the worsening of clinical symptoms in RCD patients.
DISCUSSION
In the present work, we investigated whether evaluation of different IEL parameters provides differential information with regard to mortality and morbidity in RCD patients, and their value as predictors of clinical outcome among patients with RCD. Our results show that, in RCD, morbidity is high (B60%), with the majority of patients manifesting severe symptoms within the first 2 years of RCD diagnosis, and that detection of <50% Our study differs from earlier studies evaluating clinical outcomes and prognosis of RCD. First, previous studies only analyzed mortality as the clinical outcome. Yet, as it is well known that not all patients with RCD die, and persistent or refractory symptoms despite treatment are common, 13, 15 we chose morbidity as the main clinical outcome for the current study. Second, the clinical classification of RCD has been quite variable in prior studies with regard to the assessment of mortality and mortality predictors in RCD types I and II. Some groups have used T-cell clonality analysis by PCR, 13, 14 immunohistochemistry, 18 or flow cytometry results alone for calssification, 16 whereas others have used a combination of immunohistochemistry with either flow cytometry or T-cell receptor gene rearrangement analysis 2, 15 and have considered patients manifesting minor clones as being part of the RCD type II spectrum in some cases. Therefore, to avoid classification bias and also to determine the possible differential information provided by different IEL descriptors, we investigated mortality and morbidity as a function of different IEL parameters alone or in combination.
Our study shows that, regardless of the IEL phenotype, patients with positive serology were more likely to have a shorter time to clinical worsening compared with patients with negative serology; however, patients with negative serology were at a higher risk for worsening of symptoms if they had <50% CD3 + CD8 + IELs. Patients with <50% CD3 + CD8 + IELs and positive serology, interestingly, did not develop symptom worsening earlier than patients with positive serology alone (ie, positive serology but >50% CD3 + CD8 + IELs). According to these results, detection of <50% CD3 + CD8 + IELs by immunohistochemistry is a strong predictor of clinical worsening, regardless of age, gender, and serologic status. Patients with <50% CD3 + CD8 + IELs had a nearly 5-fold higher risk of worsening clinically within the first 2 years after diagnosis when serology was negative compared to those with >50% CD3 + CD8 + IELs. T-cell receptor gene monoclonality, on the contrary, was not found to be associated with clinical worsening on the basis of multivariate analysis in our study, despite significantly decreasing the time to development of severe symptoms in univariate analysis. This is in line with the study by Malamut et al, 2 who in a European cohort including 43 RCD type II cases found that an abnormal IEL phenotype (but not T-cell monoclonality) was predictive of poor survival after adjusting for confounders. However, our results differ from those of Rubio-Tapia et al, 13 who demonstrated that cumulative risk factors, such as monoclonality, older age, total VA, and low albumin or hemoglobin levels, predicted reduced 5-year survival rates in RCD patients. Differences in the distribution of type I and II patients, the clinical outcome studied, or the criteria used for classification of RCD type are possible explanations for the discrepancies seen among these studies. Our study, in contrast to the earlier studies describing an increased risk of death associated with the detection of an abnormal IEL phenotype, focused on determining whether the frequency of CD3 + CD8 À IELs, which for the most part represent gd T cells in non-RCD type II patients, could predict increased morbidity.
In the current study the worse clinical outcome associated with patients with <50% CD3 + CD8 + IELs (CD3 + CD8 À by immunohistochemistry) and a monoclonal TCR gene rearrangement, who had an approximately 50% mortality rate, could be ascribed to expansions of TCR ab + CD3 + CD8 À IELs, which is characteristic of RCD type II. Monoclonal expansions of phenotypically aberrant IELs, considered by some to represent a "cryptic" form of EATL, likely represent an early stage in the development of overt EATL, 2,17 which has a poor prognosis, leading to rapid onset of severe symptoms and death. 9 Presence of monoclonal IEL populations in patients with high mortality in our study is in keeping with prior studies that determined monoclonality to be a risk factor when death was considered the primary outcome and explains why in our study only patients with RCD type II died. The reason why patients with positive serology or patients with polyclonal TCR gene rearrangement and <50% CD3 + CD8 + IELs had a worse clinical outcome could be due to continual gluten exposure, as increased CD3 + CD8 À IELs corresponding to gd IELs are known to be expanded in patients with CD, especially those consuming gluten. [24] [25] [26] Positive serology despite dietary compliance in RCD patients is not rare and has been reported previously in 19% to 30% of RCD patients. 2, 13, 27 Importantly, in the current study, however, marked elevations in CD3 + CD8 À IELs seemed to be a risk factor for clinical worsening, irrespective of the serologic status, thus, gluten consumption does not appear to explain why patients with <50% CD3 + CD8 + IELs but negative serology have a worse outcome than those with <50% CD3 + CD8 + IELs and positive serology. It is possible that in these patients with positive serology and <50% CD3 + CD8 + IELs, the CD8 À IEL expansions represent increased gd IELs (indicating possible gluten ingestion), while aberrant ab IELs could account for the CD8 À IEL expansions occurring in the seronegative patients. More informative methods such as multiparameter flow cytometry, capable of detecting phenotypic aberrancies in ab and gd T-cell populations, 28 would be of benefit in analyzing IEL populations in RCD patients in future studies.
Other potential risk factors predicting clinical worsening in our study, although of borderline significance, were primary resistance to GFD and duration of untreated CD, which have also been proposed to be possible risk factors for lymphoma development. 2 All these factors point toward sustained mucosal inflammation and persistent intestinal damage (longer duration rather than severity) as predictors of refractory disease.
All together, our findings suggest that objective indicators, such as the described IEL-related parameters, may facilitate comparisons between studies and may provide a more accurate assessment of patient prognosis compared with simple categorization as RCD type I and II. Such information would allow for more targeted treatment and earlier and closer follow-up of high-risk individuals, thus reducing excess morbidity. This model should be tested in other cohorts to assess its validity and confirm whether expansions of CD3 + CD8 À IELs can be used to identify patients with a higher risk of clinical worsening and monoclonal TCR rearrangements to identify patients at higher risk of dying.
Nevertheless, there are some weaknesses in our study. First, morbidity might be underestimated, as patients lost to follow-up probably include individuals dying or doing poorly at home without being reported. Second, the results might be affected by selection bias toward patients with more severe disease, as the study was conducted in a tertiary referral center. Third, monoclonal cases with >50% CD3 + CD8 + IELs were missing, impairing the evaluation of monoclonality as an independent predictor. Furthermore, the statistical effect of monoclonality on clinical worsening might be underestimated because of the small number of RCD type II patients evaluated. Finally, flow cytometry, which is fundamental to correctly characterizing the different IEL subpopulations, 28 was only performed in a small subset of patients (data not shown), and although immunohistochemical staining would allow detection of CD3 + CD8 À IELs 20 it cannot reliably distinguish between surface and cytoplasmic CD3 expression and cannot differentiate expansions of abnormal ab IELs lacking surface CD3 and CD8 expression and normal CD8
À gd IEL populations.
In conclusion, we found high morbidity among patients with RCD types I and II. Patients with <50% CD3 + CD8 + IELs by immunohistochemistry are at an increased risk for clinical worsening within the first 2 years of RCD diagnosis, even in the absence of monoclonal TCR gene rearrangements, detection of which appears to be more related with increased mortality. A simple prognostic model based on IEL-related parameters seems to be a useful tool for risk assessment. Therefore, both, the degree of CD3 + CD8 À IEL expansions and results of TCR gene rearrangement, should be determined for disease prognostication of RCD patients.
